SG11201906392WA - Nucleoside-modified rna for inducing an immune response against zika virus - Google Patents
Nucleoside-modified rna for inducing an immune response against zika virusInfo
- Publication number
- SG11201906392WA SG11201906392WA SG11201906392WA SG11201906392WA SG11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA
- Authority
- SG
- Singapore
- Prior art keywords
- zikv
- international
- nucleoside
- mrna
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
CM . I \" c e lls ( %) .6 0,4 0.2 0.0 IL-2 4 • • • • • * • 0.8 o.e 0.4 0.2 0,0 Control ZIKV mRNA N 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIPO I PCT ill~~~~~~~~ 0mi110VIIIOH olo m1°111°11111 No oimIE (10) International Publication Number WO 2018/132537 Al (51) International Patent Classification: A61K 39/12 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/013270 (22) International Filing Date: 11 January 2018 (11.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,931 11 January 2017 (11.01.2017) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: WEISSMAN, Drew; 218 Lloyd Lane, Wyn- newood, PA 19096 (US). PARDI, Norbert; 873 N. 23rd Street, Philadelphia, PA 19130 (US). HOGAN, Michael; 2205 Fitzwater Street, Apt. 2, Philadelphia, PA 19146 (US). (74) Agent: SINGH, Pallab et al.; Riverside Law, LLP, Glen- hardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS Contml • ZIKV prM-E mRNA-LNP IFNy , 18 • • e• Control ZIKV mRNA. Go ZIKV mRNA (57) : The present invention relates to compositions and methods for inducing adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside- modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. Figure 1A 0 15 0.4 13 0.2 0.1 0.0 • • • e• • C57BL/6 iNr`
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444931P | 2017-01-11 | 2017-01-11 | |
PCT/US2018/013270 WO2018132537A1 (en) | 2017-01-11 | 2018-01-11 | Nucleoside-modified rna for inducing an immune response against zika virus |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906392WA true SG11201906392WA (en) | 2019-08-27 |
Family
ID=62839708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906392WA SG11201906392WA (en) | 2017-01-11 | 2018-01-11 | Nucleoside-modified rna for inducing an immune response against zika virus |
Country Status (10)
Country | Link |
---|---|
US (2) | US11241490B2 (en) |
EP (1) | EP3568155A4 (en) |
JP (2) | JP7317715B2 (en) |
CN (1) | CN110381994B (en) |
AU (1) | AU2018207408A1 (en) |
BR (1) | BR112019014314A2 (en) |
CA (1) | CA3049991A1 (en) |
MX (1) | MX2019008303A (en) |
SG (1) | SG11201906392WA (en) |
WO (1) | WO2018132537A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
MA42502A (en) | 2015-07-21 | 2018-05-30 | Modernatx Inc | VACCINES AGAINST INFECTIOUS DISEASE |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
EP3416683A1 (en) | 2016-02-17 | 2018-12-26 | CureVac AG | Zika virus vaccine |
CN115927399A (en) * | 2016-02-25 | 2023-04-07 | 宾夕法尼亚大学理事会 | Novel vaccine against Zika virus |
EP3532097A1 (en) * | 2016-10-27 | 2019-09-04 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019055807A1 (en) * | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Zika virus rna vaccines |
EP3723796A1 (en) | 2017-12-13 | 2020-10-21 | CureVac AG | Flavivirus vaccine |
WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
KR20230051172A (en) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | Cationic Lipids for Use in Lipid Nanoparticles |
CN115197079A (en) * | 2021-04-08 | 2022-10-18 | 厦门赛诺邦格生物科技股份有限公司 | Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition |
WO2023051926A1 (en) * | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2024055000A1 (en) * | 2022-09-09 | 2024-03-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising lipid nanoparticle vaccines that elicit a modulated immune response |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2856420A (en) | 1955-12-15 | 1958-10-14 | Minnesota Mining & Mfg | Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols |
US3340299A (en) | 1964-03-27 | 1967-09-05 | Air Reduction | Tetrasubstituted ethylene diamines |
IT949755B (en) | 1972-03-01 | 1973-06-11 | Snam Progetti | PROCEDURE FOR THE PRODUCTION OF ALUMINUM CHLOROHYDROXIDES WITH CONTROLLED CHLORINE |
JPS5122416B2 (en) | 1972-11-11 | 1976-07-09 | ||
JP4111856B2 (en) | 2002-04-12 | 2008-07-02 | 昭和電工株式会社 | Stabilized ascorbic acid derivatives |
CA2611944A1 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
ES2735531T3 (en) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | RNA containing modified nucleosides and methods of use thereof |
US20090082803A1 (en) | 2007-09-26 | 2009-03-26 | Aga Medical Corporation | Braided vascular devices having no end clamps |
US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
CA2816925C (en) | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
KR101773643B1 (en) | 2010-04-28 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | Cationic lipid |
WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
JP2014508102A (en) | 2010-11-15 | 2014-04-03 | ライフ テクノロジーズ コーポレーション | Amine-containing transfection reagents and methods for producing and using the same |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
JP2013095755A (en) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | Cationic lipid |
US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
CA2884870C (en) | 2012-08-13 | 2022-03-29 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US20160030527A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Treatment of Stroke |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
JP6881813B2 (en) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | Nucleic acid vaccine |
CN106537012B (en) | 2014-05-22 | 2019-02-12 | 福斯有限责任公司 | For valve actuator induction element and be provided with the actuator of the induction element |
SI3766916T1 (en) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
CA2984125A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
US10799575B2 (en) * | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
MA42502A (en) | 2015-07-21 | 2018-05-30 | Modernatx Inc | VACCINES AGAINST INFECTIOUS DISEASE |
EP3364950A4 (en) * | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Tropical disease vaccines |
FI3368507T3 (en) | 2015-10-28 | 2023-03-21 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
-
2018
- 2018-01-11 EP EP18738860.8A patent/EP3568155A4/en active Pending
- 2018-01-11 AU AU2018207408A patent/AU2018207408A1/en active Pending
- 2018-01-11 SG SG11201906392WA patent/SG11201906392WA/en unknown
- 2018-01-11 US US16/477,258 patent/US11241490B2/en active Active
- 2018-01-11 BR BR112019014314-9A patent/BR112019014314A2/en unknown
- 2018-01-11 MX MX2019008303A patent/MX2019008303A/en unknown
- 2018-01-11 JP JP2019558335A patent/JP7317715B2/en active Active
- 2018-01-11 CN CN201880017013.6A patent/CN110381994B/en active Active
- 2018-01-11 CA CA3049991A patent/CA3049991A1/en active Pending
- 2018-01-11 WO PCT/US2018/013270 patent/WO2018132537A1/en unknown
-
2021
- 2021-12-22 US US17/559,190 patent/US20220184201A1/en active Pending
-
2023
- 2023-07-19 JP JP2023117742A patent/JP2023134745A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019014314A2 (en) | 2020-02-18 |
AU2018207408A1 (en) | 2019-08-08 |
US20220184201A1 (en) | 2022-06-16 |
EP3568155A1 (en) | 2019-11-20 |
EP3568155A4 (en) | 2020-09-23 |
CA3049991A1 (en) | 2018-07-19 |
CN110381994B (en) | 2024-05-10 |
MX2019008303A (en) | 2019-12-02 |
JP2020505444A (en) | 2020-02-20 |
WO2018132537A1 (en) | 2018-07-19 |
US11241490B2 (en) | 2022-02-08 |
US20190358314A1 (en) | 2019-11-28 |
JP7317715B2 (en) | 2023-07-31 |
CN110381994A (en) | 2019-10-25 |
JP2023134745A (en) | 2023-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201907714UA (en) | Adeno-associated virus (aav) clade f vector and uses therefor | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201810777WA (en) | Purification of multispecific antibodies | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201806340YA (en) | Zika virus vaccine | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201808422QA (en) | Gene therapy for treating hemophilia a | |
SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof |